C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
C4 Therapeutics, Inc. (CCCC) reported a Q4 loss of $0.49 per share, missing the Zacks Consensus Estimate of a $0.44 loss. This is an improvement from the $0.68 loss per share a year ago.
February 27, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
C4 Therapeutics reported a Q4 loss of $0.49 per share, which was worse than the expected $0.44 loss. However, this is an improvement from the $0.68 loss per share a year ago.
The reported loss per share was worse than expected, which is typically negative for stock prices. However, the improvement from last year's loss may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100